FDA Called Two Sentences on a Ketamine Booth Extremely Concerning
FDA cited Alar Pharmaceuticals over claims for an investigational ketamine product. The flagged phrases show up in a lot of clinic marketing.
Read More
A High THC Dose Felt Like Psilocybin. The Study Had Four People
A Johns Hopkins pilot reported 25 mg of THC produced a psilocybin-like experience. It enrolled four participants and was funded by a cannabis foundation.
Read More
The Case That Psychedelics Sometimes Make Thinking Less Flexible
Cognitive flexibility is the standard explanation for how psychedelics work. A new review argues the acute effect may sometimes run the other way.
Read More
New Mexico Just Opened Its First Psilocybin Permits. The One Clinicians Need Is Still Coming
New Mexico began accepting psilocybin producer applications on August 17. The clinician permit has not opened, and the end of 2026 target looks unlikely.
Read More
Two Infusions a Year, Two Years of Relief: Inside a 92 Patient Fibromyalgia Ketamine Study
A Winston-Salem clinic tracked 92 fibromyalgia patients on high dose ketamine for two years. The dosing model looks nothing like standard practice.
Read More
As Psychedelic Care Gets Leaner, the Integration Work Moves Home. Our Data Says Home Is a Coin Flip
A new Canadian Journal of Psychiatry paper argues leaner psychedelic protocols displace integration work onto patients’ families. HealingMaps survey data shows those households split evenly.
Read More
A Federal Report Just Told States to Prepare for Psychedelic Approval. Ketamine Clinics Are the Template
SAMHSA told states to build the budget, licensing, and oversight machinery for psychedelic therapy before the FDA approves anything. Ketamine is not named once.
Read More
Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster
Lilly paid up to $3.8 billion for a compound whose selling point is a two hour clinic visit. Session length, not efficacy, is now the axis that separates psychedelic programs.
Read More
Oregon Tracks Psilocybin Safety for Three Days. The New Data Found Problems at Three Months
A JAMA Network Open study followed 346 people through Oregon's licensed psilocybin program. The adverse events showed up long after the state stops looking.
Read More
The VA Just Started a Phase 3 Psilocybin Trial. The Control Group Gets Psilocybin Too
The VA began enrolling 240 veterans in a phase 3 psilocybin trial on August 3. There is no placebo arm, and that changes what the study can prove.
Read More